Clarapath

Clarapath is a pioneering medical robotics company founded in 2014, with a vision to automate laboratory processes in pathology. The company's flagship product focuses on fully automating the microtomy station, aiming to enhance, standardize, and digitalize anatomic pathology. Located at the NY Genome Center, Clarapath's next-generation laboratory, extensive image repository, and analysis platform are equipped to manage the entire "tissue to bits" pipeline for specialized research projects and larger clinical needs. With a recent $16.00M Series B investment received on 17 November 2021 from Northwell Health, P5 Health Ventures, Epiphron Capital, The 4100 Group, and East Post Road Ventures, Clarapath is well-positioned to advance its mission of delivering superior quality, enhanced safety, and efficiency in lab operations. Through partnerships with both research and clinical clients, the company aims to offer higher-quality lab medicine, improved safety standards, and increased lab throughput while reducing laboratory costs and labor delays. As a biotechnology and healthcare industry player, Clarapath stands at the forefront of pioneering a future of precision in pathology with its automated solutions.